Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

NCT00750282 | Completed Phase 2 Results

• 2 other identifiers: 3117412007-002256-42
• Study Type: interventional
• Target: 422
• Locations: 5 countries
• Sites: 23

Brief Summary

The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission tomography (PET). IMP binds to amyloidal beta protein accumulating in brain tissue already from early stages of Alzheimer's disease (AD). IMP is therefore a potential tracer to be used for detecting amyloid plaques. For each subject it is required to visit the study centre during the screening phase, on the PET imaging day and for 1 follow-up visit on the next day. A telephone call for safety follow-up will be performed 7 days after IMP administration. During the screening phase the subject's medical, neurological and surgical history, specific laboratory tests related to AD, MRI of the brain and certain neuro-psychiatric tests will be performed. Clinical safety measures (physical examinations, vital signs, electrocardiogram (ECG) and laboratory tests) will be performed on the PET imaging day before IMP injection and monitored during and after two PET imaging sessions. Clinical safety measures will be performed again on the follow-up visit next day. The results of PET imaging with IMP will be compared between probable AD patients and healthy volunteers (HV). The clinical diagnosis is based on international validated and accepted criteria and established after comprehensive clinical and neuro-psychiatric examinations

Conditions

Alzheimer Disease; Amyloid Beta-Protein

Keywords

Alzheimer Disease; Amyloid beta-Protein

Outcome Measures

Primary Outcomes (2)

• Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth

  Part A: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan which was considered a match for specificity. Standard of truth was the onsite clinical diagnosis. Two Beta-Amyloid Plaque Load (BAPL) algorithms for assessing the normality/abnormality of beta-amyloid plaque load in the brain scans were used. Using algorithm A (Majority Read), a brain scan of a subject with a BAPL score of "1" (without beta-amyloid plaque load) or "2" (with minor beta-amyloid plaque load) was considered normal and a BAPL score of "3" (with significant beta-amyloid plaque load) was considered abnormal. Using algorithm B (Average), a brain scan of a subject with a BAPL score of "1" was considered normal and a brain scan with a BAPL score of "2" or "3" was considered abnormal. Algorithm B was used in Part B and in the final

  90 - 110 min after investigational medical product (IMP) injection

• Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.

  Part B: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan, ie,abnormal scan (BAPL scores "2" or "3") which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan, ie,normal scan (BAPL score "1") which was considered a match for specificity. The clinical diagnosis was established by an independent consensus panel (CP) of experts in dementia. Two independent sets of PET data reads were performed. The first set was performed by a panel of three readers who received live, instructor-led training on the visual assessment procedure. The second set was performed by a panel of five separate readers who were trained on the visual assessment procedure with electronic media.

  90 - 110 min after IMP injection

Secondary Outcomes (3)

• Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment

  45 - 60 min and 110 - 130 min after IMP injection

• Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)

  45-60 min, 90-110 min, 110-130 min

• Standard Uptake Value Ratios for Florbetaben Signal

  90-110 min post injection

Study Arms (1)

Florbetaben (BAY94-9172)

EXPERIMENTAL

Drug: Florbetaben (BAY94-9172)

Interventions

Florbetaben (BAY94-9172) DRUG

Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions

Florbetaben (BAY94-9172)

Eligibility Criteria

• Age: 55 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study:
• Is a man or woman and is \> 55 of age, whereby females must be without childbearing potential (confirmed by either: age \>/= 60; or history of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start)
• Has at least 6 years of education
• Is able to provide informed consent, understand the information provided on the purpose and conduct of the trial and to comply with study procedures
• Possesses a general health that permits adequate compliance with all study procedures
• The subject, or the subject and caregiver (for probable AD patients) will be compliant and have a high probability of completing the study
• Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable AD patients)
• Has no evidence of cognitive impairment
• Has MRI brain scan that has been judged as "normal" (age- appropriate)
• Presents with positive assessment for dementia of Alzheimer's type
• Does not fulfill the criteria Dementia with Lewy Bodies (DLB) or Vascular Dementia (VaD)
• MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease
• Has a caregiver that is willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver

You may not qualify if:

• Has any contraindication to MRI examination scan
• Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application
• Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma)
• is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable
• Has a history of exposure to any radiation \>15 milli Sieverts (mSv)/year (e.g. occupational or radiation therapy)
• Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)
• Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical
• Has a brain tumor or other intracranial lesion, a disturbance of cerebro-spinal fluid (CSF) circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery
• Has an inflammatory or infectious central nervous system (CNS) disease, e.g. multiple sclerosis, HIV, syphilis, or Creutzfeldt-Jacob disease
• Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness
• Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function)
• Has a history of alcohol or drug abuse
• Has history of severe persistent depression

Sponsors & Collaborators

• Life Molecular Imaging SA: lead

Study Sites (23)

Unknown Facility

Sun City, Arizona, 85351, United States

Location

Unknown Facility

Stanford, California, 94305, United States

Location

Unknown Facility

New Haven, Connecticut, 06510, United States

Location

Unknown Facility

New York, New York, 10016, United States

Location

Unknown Facility

New York, New York, 10032, United States

Location

Unknown Facility

The Bronx, New York, 10461, United States

Location

Unknown Facility

Providence, Rhode Island, 02906, United States

Location

Unknown Facility

Westmead, New South Wales, 2145, Australia

Location

Unknown Facility

Adelaide, South Australia, 5000, Australia

Location

Unknown Facility

Heidelberg, Victoria, 3084, Australia

Location

Unknown Facility

Erlangen, Bavaria, 91054, Germany

Location

Unknown Facility

München, Bavaria, 81377, Germany

Location

Unknown Facility

München, Bavaria, 81675, Germany

Location

Unknown Facility

Essen, North Rhine-Westphalia, 45122, Germany

Location

Unknown Facility

Jülich, North Rhine-Westphalia, 52425, Germany

Location

Unknown Facility

Münster, North Rhine-Westphalia, 48149, Germany

Location

Unknown Facility

Dresden, Saxony, 01307, Germany

Location

Unknown Facility

Leipzig, Saxony, 04103, Germany

Location

Unknown Facility

Berlin, State of Berlin, 13125, Germany

Location

Unknown Facility

Kobe, Hyōgo, 650-0017, Japan

Location

Unknown Facility

Kobe, Hyōgo, 650-0047, Japan

Location

Unknown Facility

Bunkyo-ku, Tokyo, 113-8603, Japan

Location

Unknown Facility

Zurich, Canton of Zurich, 8091, Switzerland

Location

Related Publications (2)

• Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8.

  PMID: 21481640 RESULT

• Bullich S, Roe-Vellve N, Marquie M, Landau SM, Barthel H, Villemagne VL, Sanabria A, Tartari JP, Sotolongo-Grau O, Dore V, Koglin N, Muller A, Perrotin A, Jovalekic A, De Santi S, Tarraga L, Stephens AW, Rowe CC, Sabri O, Seibyl JP, Boada M. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021 Mar 27;13(1):67. doi: 10.1186/s13195-021-00807-6.

  PMID: 33773598 DERIVED

MeSH Terms

Conditions

Alzheimer Disease; Plaque, Amyloid

Interventions

4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Dr. Juergen Hirschfeld
• Organization: Piramal Imaging

juergen.hirschfeld@piramal.com

49 30 461 1246 15

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2008
• First Posted: September 10, 2008
• Study Start: August 1, 2008
• Primary Completion: November 1, 2010
• Study Completion: November 1, 2010
• Last Updated: July 24, 2014
• Results First Posted: July 16, 2014

Record last verified: 2014-07

Locations

CH (1); DE (9); JP (3); AU (3); US (7)